[High-dose inhaled beta-2 sympathomimetics in severe bronchial asthma].
A Meyer, P Jacobsen, HELGO MAGNUSSEN
Abstract
A Meyer, P Jacobsen, HELGO MAGNUSSEN
Abstract
We made the observations that in patients with severe bronchial asthma, the inhalative dose of beta-2 sympathomimetics that was required for optimal bronchial dilation revealed a large inter-individual scatter. In 21 patients, the inhalation of a maximum of 10 metered doses of salbutamol at intervals of five minutes each, led to a mean (SD) increase in the FEV 1.0 from 1.3 (0.6) 1 to 1.8 (0.7) 1. The maximum increase in the FEV 1.0 was achieved in 10 patients following the inhalation of 1 to 3 metered doses, and in 11 patients after 4 to 10 such doses. The individual requirement for inhaleable beta-2 agonists should therefore be taken into account when planning treatment.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
We made the observations that in patients with severe bronchial asthma, the inhalative dose of beta-2 sympathomimetics that was required for optimal bronchial dilation revealed a large inter-individual scatter. In 21 patients, the inhalation of a maximum of 10 metered doses of salbutamol at intervals of five minutes each, led to a mean (SD) increase in the FEV 1.0 from 1.3 (0.6) 1 to 1.8 (0.7) 1. The maximum increase in the FEV 1.0 was achieved in 10 patients following the inhalation of 1 to 3 metered doses, and in 11 patients after 4 to 10 such doses. The individual requirement for inhaleable beta-2 agonists should therefore be taken into account when planning treatment.
Key concepts: Sympathomimetics, Salbutamol, Inhalation, Asthma, Medicine, Bronchodilator Agents, Anesthesia, Bronchodilator